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Rationale for the study 
Millions of individuals wordwide use statins to lower 
blood cholesterol [1], and perhaps as many as 1 
billion worldwide, could be potential candidates for 
statin treatment. The global market for statins is 
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Abstract 
Aim: LIFESTAT is an interdisciplinary project that leverages approaches and knowledge from medicine, the humanities and 
the social sciences to analyze the impact of statin use on health, lifestyle and well-being in cohorts of Danish citizens. The 
impetus for the study is the fact that 10% of the population in the Scandinavian countries are treated with statins in order 
to maintain good health and to avoid cardiovascular disease by counteracting high blood levels of cholesterol. The potential 
benefit of treatment with statins should be considered in light of evidence that statin use has prevalent and unintended side 
effects (e.g. myalgia, and glucose and exercise intolerance). Methods: The LIFESTAT project combines invasive human 
experiments, biomedical analyses, nationwide surveys, epidemiological studies, qualitative interviews, media content 
analyses, and ethnographic participant observations. The study investigates the biological consequences of statin treatment; 
determines the mechanism(s) by which statin use causes muscle and mitochondrial dysfunction; and analyzes achievement 
of treatment goals, people’s perception of disease risk, media influence on people’s risk and health perception, and the way 
people manage to live with the risk (personally, socially and technologically). Conclusions: The originality and success 
of LIFESTAT depend on and derive from its interdisciplinary approach, in which the disciplines converge into 
thorough and holistic study and describe the impact of statin use on the everyday life of statin users. This has 
the potential for much greater benefit than any one of the disciplines alone. Integrating traditional disciplines 
provides novel perspectives on potential current and future social, medical and personal benefits of statin use. 
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estimated to be €15 billion, and the Organisation for 
Economic Co-operation and Development (OECD) 
recently estimated that no fewer than 91 defined 
daily doses of statins are consumed per 1000 individuals 
per day [2]. The average statin user is approximately 
60 years old, but this covers a wide age range 
[3,4]. In the Nordic countries, the number of statin 
users is high and increasing (Figure 1). About 10% of 
the population in Scandinavia are treated with statins 
(Figure 1). In 2014, 612,660 Danes were treated 
with a statin in the primary sector, and this figure has 
increased by approximately 20% since 2009, although 
stagnation was observed in 2012–2013. 
Different statins are produced, each chemically a 
little different from the others, but basically they have 
the same effect: lowering of total cholesterol, and in 
particular low-density-lipoprotein cholesterol (LDLC), 
concentrations in the blood through basically the 
same mechanism. 
The 2012 European guidelines [5] indicate that 
preventive treatment with statins is appropriate in 
individuals with >10% predicted risk of a major vascular 
event within 5 years, while some opinion leaders 
advocate a 5% threshold [6]. If the guidelines 
become more liberal, the number of users will probably 
increase dramatically, and the consequences of 
this are currently being debated internationally [7]. 
The downside of statins is the side effects, of which 
myalgia (muscle pain or aching, stiffness, tenderness 
or cramps) occurs in 7–29% of statin users [8] and 
more frequently (> 60%) in physically active athletes 
[9,10]. Myalgia is a strong disincentive to regular 
exercise [4,9]. However, a recent study found that statin 
users in the USA do not take less exercise than a 
comparable control group [11]. However, as stated in 
an accompanying editorial [12], a reverse causality 
may come into play: “…a decrease in exercise levels 
potentially resulted in adverse physiological and clinical 
responses, including hypercholesterolemia, which 
prompted the initiation of statin therapy, rather than 
statin therapy reducing the level of habitual physical 
activity”. Thus, the impact of statin therapy on exercise 
capacity and habits is still an open question. 
Regular exercise is one of the critical lifestyle 
approaches to preventing cardiovascular disease 
(CVD) and reducing blood cholesterol; any decrease 
in daily physical activity is a significant negative 
aspect of statin use. In addition, regular exercise is 
also effective in preventing and treating obesity and 
type 2 diabetes, which themselves are risk factors for 
CVD. Moreover, statin use is linked to increased 
incidence of type 2 diabetes [13], decreased insulin 
sensitivity [14], and impaired glucose metabolism 
and tolerance [15]. Currently, the only way to mitigate 
statin-induced myalgia is to discontinue treatment 
with statins, because the mechanistic basis of 
statin-induced myalgia is poorly understood. Detailed 
physiological and biochemical information from 
patients on statins with and without myalgia, during 
exercise or at rest, is lacking. Also, biomarkers for 
myalgia are yet to be found. Biomarkers provide a 
dynamic and powerful approach to understanding 
the spectrum of side effects of statin treatment. 
Defined as alterations in the constituents of tissues or 
body fluids, these markers offer the means for homogeneous 
classification of statin risk factors, and they 
can extend our basic information about the underlying 
pathogenesis of myalgia. 
 
 
 
 
Figure 1. U sers of statins (Simvastatin, Lovastatin, Pravastatin, Fluvastatin, Atorvastatin, or 
Rosuvastatin) 2004–2014 in Denmark, Norway and Sweden prescribed in the primary healthcare 
sector, users/1000 persons. Sources: Medstat.dk; Reseptregisteret.no; Socialstyrelsen.se. 
 
Statins are effective in reducing blood cholesterol, 
and some studies with hard end points have 
indeed shown that statin treatment significantly 
reduces the frequency of coronary heart disease 
[16]. Furthermore, the effect of statins is modified 
by the genetic composition of the individual, such 
that people with the highest burden of genetic risk 
derive the largest relative and absolute clinical benefit 
from statin therapy [17]. In primary prevention, 
the absolute risk reduction per year for one major 
vascular event (not necessarily death) ranges from 
0.2% to 2.4% in people with a low (<5%) and a 
high (>30%) 5-year risk, respectively [6]. The corresponding 
numbers needed to treat range from 
500 to 42, respectively. Thus, a relatively large number 
of people in primary prevention may receive 
medication throughout life in order to treat a risk 
factor. 
The decision to initiate, maintain and eventually 
terminate statin treatment is, however, not entirely a 
decision based upon biomedical knowledge. 
However, there are currently no interdisciplinary 
research missions to explore the complicated interplay 
between medical knowledge and media discourses 
on statins vis-à-vis the subjective perception 
of risk and the individual attitude toward the use of 
medicine and technology. 
The purpose of the present research endeavor, 
“LIFESTAT – Living with statins”, is to produce 
new knowledge on this issue, that is, to combine 
knowledge from medicine, the humanities and the 
social sciences to analyze the impact of statin use on 
health, lifestyle and well-being in a cohort of Danish 
citizens. The vision is that the decision to initiate statin 
treatment in people and the predominantly biomedical 
international discussion will be based upon a 
holistic view of the challenges of statin treatment. 
 
Studying the body at risk 
Over the past 50 years, an ever-expanding focus on 
risk and risk prevention has come to define much of 
contemporary healthcare in western societies. Thus, 
the increased prescription of statins can be interpreted 
as a result of a shift in western societies from 
looking at “the diseased body” to “the body at risk” 
[18–20] and from focusing on curative health to also 
taking into consideration preventive health. This shift 
is crucial for the way the average citizen views his or 
her own health status and lives his or her life. The ethnographic 
part of the LIFESTAT project focuses on 
the case of increased levels of cholesterol and the use 
of statins to remedy this condition as an example of a 
new model of preventive health programming. Using 
well-established qualitative methods (interviews, 
focus groups and observations) to study the everyday 
life of a sub-cohort of 50 individuals, the project will 
study how this development will impact the everyday 
life of aging Danes. 
Furthermore, qualitative interviews and participant 
observation will be conducted with participants 
in the laboratory research that is undertaken for the 
LIFESTAT project. Parallel with this focus on the 
individual (potential) statin user, the study will also 
examine the mechanisms by which the statistical calculation 
of risk has come to define health services 
and their modalities, i.e. through the medication of 
at-risk conditions. Arguably, prevention is also 
becoming increasingly commercialized, given that 
health checks are being offered in workplaces and 
other environments outside of the clinic, while measurement 
devices, health gadgets and dietary supplements 
are on sale from a wide range of suppliers, 
ranging from supermarkets through hardware stores 
to pharmacies. Thus, the ethnographic study of statin 
use in Denmark will include a focus on the individual 
(potential) statin user, away from questions pertaining 
to knowledge production in laboratories and 
toward social, cultural and political complexities of 
current healthcare. 
 
Media influences on statin use and 
health perception 
Studying people’s risk behavior and health perceptions, 
related in this case to cholesterol and statins, 
has to take into consideration the fact that media play 
an important role in affecting people’s ideas of health 
and well-being. Newspapers, television programs 
and lifestyle magazines as well as websites on the 
Internet are concerned with topics related to health 
and disease. The media are a very important source 
of information and a central way that people are 
informed about health-related issues in general. 
Equally important, however, is how people are 
informed about health, risk and disease. A comprehensive 
textual analysis consisting of a quantitative 
content and a qualitative discourse analysis will be 
conducted with the aim of studying how the media 
communicate issues related to cholesterol, statins 
and health. Using a framing theoretical point of 
departure [21,22], media content is regarded as decisive 
for people’s knowledge and understanding of 
things, how they relate to the world, and which opinions 
they communicate to other people. Thus, media 
presentation of cholesterol and statins is an important 
analytical topic that may influence people’s initiative 
to start or to stop treatment with statins. The 
basis of this investigation is 3 years’ media output 
relating to statins from two major newspapers and 
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two lifestyle magazines, all based in Denmark (n>700 
articles). 
A representative survey instrument has been 
developed to collect data from 3000 respondents to 
increase the knowledge of how information on cholesterol 
and statins is disseminated to the public and 
how this information influences the individual citizen 
as patient, pharmaceutical user and personal risk 
manager. Besides functioning as sources of information 
and knowledge, the media are an important 
arena for communication of health issues and hence 
for decision making. In particular, the Internet has 
become a popular place both to look for health and 
medical information and for people to share their 
experiences with other people [23]. Key questions of 
the media survey concern which media, when (before 
or after people were diagnosed), how often people 
consult media on health issues and on cholesterol, 
compared with visiting the physician, and how much 
time they spend seeking health information. An 
important issue is connected to people’s evaluation 
of the reliability of the sources of knowledge. How do 
people evaluate information on cholesterol and statins 
provided by the media, the physician and health 
institutions in general: do they find all information 
equally reliable? Has the possibility of seeking health 
information on the Internet changed people’s relation 
to the physician and official health institutions, 
and if so, how? The survey will thus provide an initial 
picture of how people use media as knowledge 
sources. Finally, the question is whether people feel 
more secure or whether they become more concerned 
about their health when media are used as the 
knowledge source on disease. 
 
Media coverage of side effects, 
information-seeking style and statin use 
As mentioned above, many factors are to be considered 
when there is a high level of cholesterol in the 
blood, and there are also many individual ways of 
handling treatment with statins. 
At the same time as statins are being prescribed to 
an increasing part of the Danish population, during 
the past 15 years a large proportion of those who are 
prescribed statins do not redeem prescriptions, and 
among those who do, about half stop treatment. 
General practitioners (GPs) are generally hesitant to 
stop treatment, and the decision not to take statins is 
very often made by the individual user, expressed 
in medical terms as “non-compliance” [24,25]. 
Information from the media is likely to play a role in 
this decision. Media set the agenda for which topics 
are discussed in the general population. The benefits 
and harms of statins as a risk-reducing drug are discussed 
among researchers, and this is reflected in the 
media. 
However, information from the media is not passively 
transferred to the general public; it is also 
actively sought and processed by the statin user. In 
this process, socioeconomic status, lifestyle and 
beliefs about medicines also play a role. From a public 
health perspective, the LIFESTAT project contributes 
to the discussion on the use of statins in the 
general population in two sub-projects. 
First, we will use a quasi-experimental design to 
study whether statin use was affected by a strongly 
negatively framed newspaper article from 2008. The 
hypothesis is that those using statins for primary prevention 
are likely to be more influenced by external 
factors compared with those using statins after, for 
instance, a myocardial infarction. The data for this 
study will be register data for the entire Danish population. 
Information on prescriptions is available from 
the Danish National Prescription Database, and 
information on disease status is available from the 
national hospital register and use of selected medications. 
Further, register data on age, sex and socioeconomic 
factors are available. 
Second, we will focus on factors influencing statin 
use at the individual level. This study will address the 
question of how knowledge about cholesterol and 
statins, information-seeking strategy, lifestyle and 
beliefs about medicines may influence statin use. We 
will collect this information from the national survey, 
and by linking survey data to the Danish National 
Prescription Database, actual purchases of statins 
among the survey respondents can be studied. In the 
survey, we will measure information-seeking style 
with the Threatening Medical Situations Inventory 
(TMSI), which classifies individuals on a continuum 
of two scales: “active seekers” and “information 
avoiders”. Seeking information on stopping treatment 
is categorized as being a previous user, and 
measures of non-adherence include intentional and 
unintentional non-adherence. The hypothesis is that 
“active seekers” of information are more likely to be 
intentional non-adherers, while “information avoiders” 
are more likely to be unintentional non-adherers. 
Epidemiological and statistical methods will be 
used to study associations, taking into consideration 
the role of educational background, lifestyle and 
beliefs about medicines. 
 
General practice 
In treatment with statins, the individual patient and 
clinical guidelines are the cornerstones for the decisions 
by the GP. The guideline defines the goals for 
treatment and identifies high-risk patients who will 
benefit from therapy. These treatment goals are based 
on the present evidence for reducing morbidity and 
mortality connected to different medical conditions. 
The goals have been sharpened in recent years, and 
experts recommend more aggressive treatment with 
statins [26], although full agreement has not been 
achieved [27]. Compared with primary prevention, 
statin therapy is more important in secondary prevention, 
e.g. for patients suffering from CVD and 
diabetes. It is crucial to identify these patients for statin 
therapy. It is important when planning healthcare 
to identify groups in the population with special 
problems in relation to treatment with lipid-lowering 
drugs. The question is whether the detection of 
patients for secondary prevention by the healthcare 
system is influenced by socio-demographic and other 
individual factors. These issues will be examined 
using data (diagnosis, level of cholesterol, treatment, 
disposition and socio-demographic factors) from a 
population study (The Danish General Suburban 
Population Study (GESUS)) including 20,876 persons 
[28]. Another problem in relation to treatment 
with statins in general practice is side effects, which 
will be addressed in the following section. 
 
Biomedical perspectives 
The mechanism behind statin-induced myalgia is 
unresolved [8]. Previous studies have shown that 
myalgic patients on statin treatment are slower to 
reach peak power output [14], but muscle strength 
and other measures of muscle performance do not 
seem to be affected by statin treatment per se [11,29]. 
However, statins have been shown to have deleterious 
effects on skeletal muscle mitochondrial function 
[15], and some authors believe that statin-induced 
myopathy relates to an inhibitory effect on mitochondrial 
complex III [30]. 
Another unwanted side effect of statin treatment 
is that these drugs increase the risk of type 2 diabetes, 
and glucose tolerance deteriorates [15]. The mechanism 
for this effect is also not resolved. One likely 
scenario could be that the effect of statins on skeletal 
muscle function paves the way for a vicious circle 
leading to physical inactivity, which, in turn, will 
cause diminished insulin sensitivity, weight gain and 
lack of stimulus for mitochondrial biogenesis. A 
physically inactive lifestyle combined with obesity 
will then promote elevation of cholesterol levels. 
The impact of statin treatment on physical performance, 
muscle and mitochondrial function as 
well as on glucose homeostasis will be studied in 
ca. 50 patients with and without myalgia and 
appropriate control subjects. Thorough phenotypic 
characterization through state-of-the-art methods 
(glucose clamps, intravenous and oral glucose tolerance 
tests, muscle power and fitness), including 
analysis of muscle and adipose tissue biopsies, will 
pave the way for delineating the mechanism behind 
statin-induced myalgia and identification of a 
potential biomarker for myalgia. 
 
Potential of the study 
Via the multidisciplinary approach, the present 
research project will enable a description of the many 
facets of initiating, maintaining and ending statin 
treatment in patients with elevated cholesterol levels 
in the blood. In particular, the factors that determine 
people’s choice to accept or decline medication will 
be defined, which is of practical clinical use in primary 
healthcare, where the vast majority of this drug 
is prescribed. Furthermore, knowledge of the interaction 
of statins with muscle function will create 
opportunities for tailored treatment and potential 
alleviation of the most common side effect, myalgia, 
which is the primary reason for patients to discontinue 
treatment. The content analysis of a broad sample 
of print media output will provide new information 
on the ways in which knowledge about these issues is 
disseminated to the public, and the national survey 
will, for the first time, shed light on the influence of 
media on people’s information-seeking behavior and 
perception of cholesterol and statin medication. 
These two media investigations are new within the 
area of media and communication research, and will 
contribute significantly to the discussion of what 
influences people’s perception of risk and health in 
general. 
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